CBD Brands Line Up for Medicare Pilot as Federal Healthcare Pathway Opens
cbdMD, NuLeaf Naturals, and Vlasic Labs move fast after CMS launches first structured program for hemp-derived CBD in Medicare
By CBDWorldNews Editorial Staff | April 21, 2026
Three CBD companies have publicly staked their positions in the new Medicare pilot program that took effect April 1, marking the first time hemp-derived CBD products have a structured federal healthcare pathway.
The Program
The Substance Access Beneficiary Engagement Incentive (BEI), administered by the Centers for Medicare & Medicaid Services (CMS), allows participating healthcare organizations to furnish eligible hemp-derived CBD products to Medicare patients. The program covers organizations in CMS Innovation Center models including ACO REACH, the Enhancing Oncology Model (EOM), and the upcoming LEAD Model launching January 2027.
An FDA enforcement memo from Commissioner Marty Makary cleared the path. The agency stated it “does not intend to enforce” food and drug law provisions against orally administered, hemp-derived CBD products that meet specific requirements. That discretion opens the door for CMS to move forward without a direct collision with existing regulations.
The program does not reimburse product costs through Medicare. Participating organizations independently determine supplier relationships, and there are no designated preferred vendors.
Who’s Moving
cbdMD launched a dedicated clinical healthcare channel on April 1, the same day the BEI took effect. The Charlotte, North Carolina-based company (NYSE American: YCBD) is pitching its regulatory portfolio—including a published 90-day OECD 408 toxicity study, IRB-approved human trial data, and self-affirmed GRAS dossiers—as the entry ticket for physician-supervised programs.
“Healthcare is where this category has always needed to go. This is the inflection point.” — Ronan Kennedy, CEO, cbdMD
Sibyl Swift, Ph.D., a cbdMD board member, noted the clinical bar is high: “They require OECD-standard toxicology, human clinical data, drug interaction transparency.”
NuLeaf Naturals, the U.S. hemp-derived CBD subsidiary of Canadian company High Tide Inc., announced it would pursue participation and has already begun engaging with participating organizations. NuLeaf brings its own manufacturing and third-party testing infrastructure to the table.
Vlasic Labs confirmed its CBD product line meets the current CMS qualifications, positioning it as another early supplier candidate.
What This Means for the Industry
The Medicare pathway represents a fundamental shift in how CBD reaches consumers. Instead of competing for shelf space in wellness aisles, brands now have a route into clinical settings with physician oversight and patient populations that skew older and more health-focused.
For companies that have invested in clinical data and regulatory compliance, the pilot validates years of spending that produced no direct revenue. For brands without that infrastructure, the gap just widened.
The quality of lab testing and documentation that companies bring to this program will separate participants from bystanders. Products need batch-level traceability and healthcare-grade supply chains—standards that go well beyond what most retail CBD brands currently maintain.
The Catch
Anti-cannabis groups have not sat idle. Smart Approaches to Marijuana filed suit in federal court to block the program, characterizing it as coverage of non-FDA-approved products. A hearing was scheduled for April 20. The outcome of that challenge could slow or halt the pilot before it gains momentum.
The FDA’s enforcement discretion is also not permanent regulation. A future commissioner could reverse the memo, leaving the program without its legal foundation.
Still, for an industry that has spent years asking for a federal pathway, these first steps through healthcare carry more weight than any retail expansion. Companies with strong product portfolios and clinical backing are best positioned to benefit.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.
